Published in Ann N Y Acad Sci on April 01, 2008
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab (2012) 1.35
Redox regulation of mitochondrial function with emphasis on cysteine oxidation reactions. Redox Biol (2013) 1.28
Cardiac anaplerosis in health and disease: food for thought. Cardiovasc Res (2011) 1.09
Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep (2013) 1.08
The succinated proteome. Mass Spectrom Rev (2013) 0.89
Hyperglycemic Stress and Carbon Stress in Diabetic Glucotoxicity. Aging Dis (2016) 0.88
Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and "cryptic targets" of transcription factors. Chin J Cancer (2012) 0.84
Protein Modifications as Manifestations of Hyperglycemic Glucotoxicity in Diabetes and Its Complications. Biochem Insights (2016) 0.79
Oncometabolites: Unconventional triggers of oncogenic signalling cascades. Free Radic Biol Med (2016) 0.78
Novel insights into FH-associated disease are KEAPing the lid on oncogenic HIF signalling. Oncotarget (2011) 0.76
The pathobiology of diabetic complications: a unifying mechanism. Diabetes (2005) 14.96
A common mechanism of cellular death induced by bactericidal antibiotics. Cell (2007) 12.92
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 12.33
The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem (2004) 3.31
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest (2003) 2.95
S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch Biochem Biophys (2006) 1.46
Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress. J Biol Chem (2007) 1.38
A mechanistic view of mitochondrial death decision pores. Braz J Med Biol Res (2007) 1.19
Proteomic analysis of the site specificity of glycation and carboxymethylation of ribonuclease. J Proteome Res (2003) 1.11
Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol Genomics (2003) 3.84
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes (2007) 2.51
Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol (2011) 2.45
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol (2005) 1.95
Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum (2002) 1.85
Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol (2005) 1.82
Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care (2007) 1.73
Mice deficient in both Mn superoxide dismutase and glutathione peroxidase-1 have increased oxidative damage and a greater incidence of pathology but no reduction in longevity. J Gerontol A Biol Sci Med Sci (2009) 1.65
Is human aging still mysterious enough to be left only to scientists? Bioessays (2002) 1.59
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int (2002) 1.48
S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch Biochem Biophys (2006) 1.46
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol (2009) 1.45
Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress. J Biol Chem (2007) 1.38
The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes (2002) 1.35
A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res (2009) 1.31
Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes (2012) 1.24
The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS One (2011) 1.20
A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem (2001) 1.19
Muscle oxidative capacity during IL-6-dependent cancer cachexia. Am J Physiol Regul Integr Comp Physiol (2010) 1.19
Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci (2005) 1.17
Enrichment and analysis of nonenzymatically glycated peptides: boronate affinity chromatography coupled with electron-transfer dissociation mass spectrometry. J Proteome Res (2007) 1.17
Succination of thiol groups in adipose tissue proteins in diabetes: succination inhibits polymerization and secretion of adiponectin. J Biol Chem (2009) 1.14
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology (2006) 1.13
The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int (2003) 1.13
Proteomic analysis of the site specificity of glycation and carboxymethylation of ribonuclease. J Proteome Res (2003) 1.11
Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. FASEB J (2007) 1.08
Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes (2005) 1.08
Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. Biochim Biophys Acta (2011) 1.05
The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta (2005) 1.03
Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res (2004) 1.03
The effect of exercise on IL-6-induced cachexia in the Apc ( Min/+) mouse. J Cachexia Sarcopenia Muscle (2011) 1.03
IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse. Skelet Muscle (2012) 1.02
Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem (2003) 1.02
Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res (2008) 1.02
Cadmium and mercury cause an oxidative stress-induced endothelial dysfunction. Biometals (2006) 0.98
Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys (2003) 0.96
Chemical modification of proteins during peroxidation of phospholipids. J Lipid Res (2005) 0.96
Succination of proteins in diabetes. Free Radic Res (2010) 0.96
Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res (2002) 0.95
Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol (2005) 0.94
Chelation therapy: overlooked in the treatment and prevention of diabetes complications? Future Med Chem (2013) 0.94
Tissue-specific variation in glycation of proteins in diabetes: evidence for a functional role of amadoriase enzymes. Ann N Y Acad Sci (2005) 0.91
Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats. Biochem Biophys Res Commun (2010) 0.91
Mitochondrial stress causes increased succination of proteins in adipocytes in response to glucotoxicity. Biochem J (2012) 0.91
Menadione causes endothelial barrier failure by a direct effect on intracellular thiols, independent of reactive oxidant production. Biochim Biophys Acta (2003) 0.90
The succinated proteome. Mass Spectrom Rev (2013) 0.89
Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications (2008) 0.88
Dietary bread crust advanced glycation end products bind to the receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral administration to healthy and subtotally nephrectomized rats. Ann N Y Acad Sci (2005) 0.87
Chemical modification of muscle protein in diabetes. Arch Biochem Biophys (2004) 0.87
What is the future of diabetic wound care? Diabetes Educ (2006) 0.86
AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys (2003) 0.86
N epsilon-(carboxymethyl)lysine (CML) as a biomarker of oxidative stress in long-lived tissue proteins. Methods Mol Biol (2002) 0.86
Tissue distribution of S-(2-succino)cysteine (2SC), a biomarker of mitochondrial stress in obesity and diabetes. Obesity (Silver Spring) (2011) 0.86
Detection and identification of arginine modifications on methylglyoxal-modified ribonuclease by mass spectrometric analysis. J Mass Spectrom (2007) 0.85
Glutaraldehyde is an effective cross-linker for production of antibodies against advanced glycation end-products. J Immunol Methods (2008) 0.84
Elements of diabetic nephropathy in a patient with GLUT 2 deficiency. Mol Genet Metab (2005) 0.84
Chelation therapy for the management of diabetic complications: a hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma. Clin Chem Lab Med (2014) 0.83
Renal effects of oral maillard reaction product load in the form of bread crusts in healthy and subtotally nephrectomized rats. Ann N Y Acad Sci (2005) 0.83
Proteomic analysis of arginine adducts on glyoxal-modified ribonuclease. Mol Cell Proteomics (2004) 0.82
Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy. Curr Pharm Des (2004) 0.82
Improved methods for the enrichment and analysis of glycated peptides. Anal Chem (2008) 0.81
Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells. Ann N Y Acad Sci (2005) 0.81
The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl (2004) 0.81
Lipid peroxidation and protein modification in a mouse model of chronic iron overload. Metabolism (2002) 0.80
Lipid-derived modifications of plasma proteins in experimental and human diabetes. Ann N Y Acad Sci (2005) 0.79
Development of an UPLC mass spectrometry method for measurement of myofibrillar protein synthesis: application to analysis of murine muscles during cancer cachexia. J Appl Physiol (1985) (2013) 0.78
Formation of methionine sulfoxide during glycoxidation and lipoxidation of ribonuclease A. Arch Biochem Biophys (2006) 0.77
In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes. Metabolism (2004) 0.77
Effect of glucose concentration on formation of AGEs in erythrocytes in vitro. Ann N Y Acad Sci (2005) 0.76
The immunogenicity of modified lipoproteins. Ann N Y Acad Sci (2005) 0.76
The clinical chemome: a tool for the diagnosis and management of chronic disease. Clin Chem (2004) 0.76
Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats. Nephrol Dial Transplant (2005) 0.76